67127-78-0

Basic information

• Product Name: 3-acetyl-2-hydroxybenzoic acid
• Synonyms: 3-acetyl-2-hydroxybenzoic acid
• CAS NO: 67127-78-0
• Molecular Weight: 180.16
• Mol File: 67127-78-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-acetyl-2-hydroxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-acetyl-2-hydroxybenzoic acid(67127-78-0)
• EPA Substance Registry System: 3-acetyl-2-hydroxybenzoic acid(67127-78-0)

Safety Data

• Hazardous Substances Data: 67127-78-0(Hazardous Substances Data)

Upstream product

• 55108-29-7 3-formyl-2-hydroxyacetophenone 
• 7440-44-0 pyrographite 
• 67127-96-2 1-<2-hydroxy-3-(prop-1-enyl)phenyl>ethanone 
• 58621-39-9 2-acetyl-6-allylphenol 
• 1503-53-3 2-acetyloxy-5-bromobenzoic acid 
• 89-55-4 5-bromosalicyclic acid 
• 1760-84-5 2-hydroxy-3-acetyl-5-bromobenzoic acid 

Downstream Products

• 77527-00-5 methyl 2-hydroxy-3-acetylbenzoate 
• 1219446-68-0 (E)-2-hydroxy-3-(3-(3-(trifluoromethyl)phenyl)acryloyl)benzoic acid 
• 57553-05-6 3-(2-acetoxy-benzoylimino)-1-phenyl-3H-1λ⁴-benzo[d]isothiazole 1-oxide 
• 187272-62-4 3'-carboxy-2'-hydroxy-4-(2-quinolinylmethoxy)chalcone 
• 67127-40-6 3-acetyl-2-hydroxy-5-sulfamoyl-N-1H-tetrazol-5-ylbenzamide 
• 67127-62-2 3-acetyl-2-hydroxy-5-nitro-N-1H-tetrazol-5-ylbenzamide 
• 100245-52-1 3-acetyl-2-hydroxy-5-(chlorosulfonyl)-N-(1H-tetrazol-5-yl)benzamide 
• 92606-13-8 4'-methylflavone-8-carboxylic acid 
• 185347-16-4 2-Hydroxy-3-((E)-3-p-tolyl-acryloyl)-benzoic acid 
• 187272-75-9 3'-carboxy-2'-hydroxy-4-[2-(2-quinolinyl)ethenyl]chalcone 
• 187272-79-3 3'-carboxy-2'-hydroxy-3-[2-(2-quinolinyl)ethenyl]chalcone 
• 187272-66-8 3'-carboxy-2'-hydroxy-3-(2-quinolinylmethoxy)chalcone 
• 100245-36-1 3-Acetyl-2-hydroxy-5-nitro-benzoic acid 
• 67127-97-3 3-acetyl-2-hydroxy-N-1H-tetrazol-5-ylbenzamide 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present invention relates to compositions and methods for the treatment of HA01 -associated disorders, such as primary hyperoxaluria 1.

Chalcone derivatives and drugs containing the same

PCT No. PCT/JP97/01652 Sec. 371 Date Nov. 17, 1998 Sec. 102(e) Date Nov. 17, 1998 PCT Filed May 16, 1997 PCT Pub. No. WO97/44306 PCT Pub. Date Nov. 27, 1997This invention relates to chalcone derivatives represented by the following formula (1): wherein A represents a phenyl group, a quinolyl group or the like, W represents a vinylene group or the like, and R1 to R5 each independently represent a carboxyl, cyano, alkyloxycarbonyl or like group, or salts of the chalcone derivatives, and also to drugs containing them as effective ingredients. These compounds have excellent cys-LT receptor antagonism, and are useful as antiallergic agents or the like.

Synthesis of carboxylated flavonoids as new leads for LTD4 antagonists

A series of 3'- and 5'-carboxylated chalcones, 6- or 8-carboxylated flavones and 6-carboxylated flavanones, -flavanols and -flavans were prepared. The compounds were tested for their inhibitory activities against leukotriene D4 (LTD4) induced contraction of guinea-pig ileum. A new and convenient synthetic route to 3-acetyl-2-hydroxybenzoic acid (Id), a key intermediate for the synthesis of 3'-carboxy-2'-hydroxychalcones and 8-carboxylated flavones, was developed. The activities of the tested compounds ranged from 0 to 63% inhibition at 10-5 M drug concentration against a single challenge of 10-8 M LTD4. Several compounds were tested in a radioligand binding assay against [3H]LTD4 on guinea-pig lung membrane. The quinoline-containing chalcone 12 and flavone 17 were found to exhibit significant but weak affinities for LTD4 receptors with pK(D)-values of 4.95 and 4.83, respectively and are interesting lead structures for the development of rigid LTD4 antagonists. In contrast, the rest of the compounds tested in the binding assay did not show significant displacement of the radioligand, implying that for these compounds the functional activity is probably not caused by competitive antagonism at the LTD4 receptor. The exact mechanism of the relaxant activity remains unclear.